SPIRIVA RESPIMAT 2.5 mcg
offers unparalleled support
for your patients along their
COPD treatment journey
-
*
Terms and Conditions Apply.
![chevron external link]( "chevron external link")
-
†
Source: Fingertip Formulary, health plan or state listed above, and/or data on file, Boehringer lngelheim Pharmaceuticals, Inc. as of 02/01/2024. Placement on formulary does not establish clinical comparability of products, including safety and efficacy, and is not a guarantee of full or partial coverage and/or payment. Contact health plan, state, or www.medicare.gov for most current information, as it is subject to change without notice. This is not intended to be an exhaustive list of all plans in your area. Boehringer lngelheim Pharmaceuticals, Inc. does not sponsor or endorse any particular plan. Utilization controls/restrictions may vary from plan to plan. Provider communication only—not approved for prescription drug plan member distribution. Information is subject to change without notice.
GET ACCESS
SPIRIVA RESPIMAT—the #1 prescribed LAMA among pulmonologists is also affordable1†
$35 Co-pay Savings
Eligible patients pay as little as $35 for a 30-day prescription fill with the SPIRIVA RESPIMAT Savings Card1*
LAMA, long-acting antimuscarinic agent.
†Terms and Conditions Apply.
Unrestricted access and best-in-class coverage
for COPD1
SPIRIVA RESPIMAT has up to 92% aggregate access—and best-in-class coverage—over the most commonly prescribed LAMA DPIs*
LAMA, long-acting antimuscarinic agent; DPI, dry powder inhaler.
Boehringer Ingelheim Pharmaceuticals, Inc. either owns or uses the SPIRIVA® RESPIMAT®, SPIRIVA® HANDIHALER®, and STIOLTO® RESPIMAT® trademarks under license. The other trademarks referenced above are owned by third parties not affiliated with Boehringer Ingelheim Pharmaceuticals, Inc.
-
*
Source: Fingertip Formulary, health plan or state listed above, and/or data on file, Boehringer Ingelheim Pharmaceuticals, Inc. as of 02/01/2024. Placement on formulary does not establish clinical comparability of products, including safety and efficacy, and is not a guarantee of full or partial coverage and/or payment. Contact health plan, state, or www.medicare.gov for most current information, as it is subject to change without notice. This is not intended to be an exhaustive list of all plans in your area. Boehringer lngelheim Pharmaceuticals, Inc. does not sponsor or endorse any particular plan. Utilization controls/restrictions may vary from plan to plan. Provider communication only—not approved for prescription drug plan member distribution. Information is subject to change without notice.
GET STARTED
Support and tools that help your patients with COPD start and stay on SPIRIVA RESPIMAT
For patients starting treatmentThe Choose the Mist Onboarding Kit helps patients get started on their RESPIMAT® inhaler successfully
- Materials on how to use the RESPIMAT inhaler
- Information on savings and support programs
- Real stories from other patients
- FAQs
For patients already on treatmentPatients can receive ongoing, personalized support throughout their treatment journey at the Inhaleability HUB.
content
Inhaleability HUB resources that help patients start and stay on treatment:
Local air quality data updated in real time for accuracy
The interactive MyActivity Tracker to help patients set and achieve goals
Tools and other helpful resources
SPIRIVA RESPIMAT, 2.5 mcg, and SPIRIVA HANDIHALER are indicated for the long-term, once-daily, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema, and for reducing COPD exacerbations.
SPIRIVA is not indicated for relief of acute bronchospasm.
SPIRIVA is contraindicated in patients with a history of hypersensitivity to tiotropium, ipratropium, or any component of either product. Immediate hypersensitivity reactions, including angioedema (including swelling of the lips, tongue, or throat), itching, or rash have been reported.
IMPORTANT SAFETY INFORMATION (cont’d)
SPIRIVA is intended as a once-daily maintenance treatment for COPD and should not be used for the relief of acute symptoms, i.e., as rescue therapy for the treatment of acute episodes of bronchospasm. In the event of an attack, a rapid-acting beta2-agonist should be used.
Immediate hypersensitivity reactions, including urticaria, angioedema (swelling of lips, tongue, or throat), rash, bronchospasm, anaphylaxis, or itching may occur after administration of SPIRIVA. If such a reaction occurs, discontinue SPIRIVA at once and consider alternative treatments. Given the similar structural formula of atropine to tiotropium, patients with a history of hypersensitivity reactions to atropine or its derivatives should be closely monitored for similar hypersensitivity reactions to SPIRIVA.
SPIRIVA HANDIHALER should be used with caution in patients with severe hypersensitivity to milk proteins.
Inhaled medicines, including SPIRIVA, may cause paradoxical bronchospasm. If this occurs, it should be treated with an inhaled short-acting beta2-agonist, such as albuterol. Treatment with SPIRIVA should be stopped and other treatments considered.
SPIRIVA should be used with caution in patients with narrow-angle glaucoma. Prescribers and patients should be alert for signs and symptoms of acute narrow-angle glaucoma (e.g., eye pain or discomfort, blurred vision, visual halos or colored images in association with red eyes from conjunctival congestion and corneal edema). Instruct patients to consult a physician immediately should any of these signs or symptoms develop.
Since dizziness and blurred vision may occur with the use of SPIRIVA, caution patients about engaging in activities such as driving a vehicle, or operating appliances or machinery.
SPIRIVA should be used with caution in patients with urinary retention. Prescribers and patients should be alert for signs and symptoms of urinary retention (e.g., difficulty passing urine, painful urination), especially in patients with prostatic hyperplasia or bladder-neck obstruction. Instruct patients to consult a physician immediately should any of these signs or symptoms develop.
Patients with moderate to severe renal impairment (creatinine clearance of <60 mL/min) and treated with SPIRIVA should be monitored closely for anticholinergic side effects.
The most common adverse reactions >3% incidence and higher than placebo with SPIRIVA RESPIMAT (placebo) in COPD trials were pharyngitis 11.5% (10.1%), cough 5.8% (5.5%), dry mouth 4.1% (1.6%), and sinusitis 3.1% (2.7%).
The most common adverse reactions >5% incidence and exceeded placebo by ≥1% with SPIRIVA HANDIHALER (placebo) in COPD trials were upper respiratory tract infection 41% (37%), dry mouth 16% (3%), sinusitis 11% (9%), pharyngitis 9% (7%), non-specific chest pain 7% (5%), urinary tract infection 7% (5%), dyspepsia 6% (5%), and rhinitis 6% (5%). In addition, the most common reported adverse reaction ≥3% incidence and higher than placebo from the 4-year trial with SPIRIVA HANDIHALER (placebo) not included above were headache 5.7% (4.5%), depression 4.4% (3.3%), insomnia 4.4% (3.0%), and arthralgia 4.2% (3.1%).
SPIRIVA may interact additively with concomitantly used anticholinergic medications. Avoid coadministration with other anticholinergic-containing drugs.
SPIRIVA capsules should not be swallowed and should only be inhaled through the mouth (oral inhalation) using the HANDIHALER device, and the HANDIHALER device should not be used for administering other medications.
Inform patients not to spray SPIRIVA RESPIMAT into the eyes as this may cause blurring of vision and pupil dilation.
Please see full Prescribing Information for SPIRIVA RESPIMAT, including Instructions for Use, and full Prescribing Information for SPIRIVA HANDIHALER, including Patient Information and Instructions for Use.
CL-SVR-0036 2.8.2016
REFERENCE
-
Data on file. Boehringer Ingelheim Pharmaceuticals, Inc.